HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Portfolio Pulse from
Soligenix, Inc. announced positive interim results from an ongoing study of HyBryte™ for early-stage cutaneous T-cell lymphoma, supported by a $2.6 million FDA grant.
January 14, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soligenix, Inc. announced positive interim results from a study on HyBryte™ for early-stage cutaneous T-cell lymphoma, supported by a $2.6 million FDA grant.
The positive interim results from the HyBryte™ study, along with the support of a significant FDA grant, are likely to boost investor confidence in Soligenix's product pipeline, potentially leading to a positive impact on SNGX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100